Alec Stranahan

“First, on time on treatment in the commercial setting, Do you think the energized studies are a good barometer here? Just trying to think about how the dynamic of patients potentially coming off their P could play into second-half sales.”

“I guess one on MPS2 and then one follow-up on Affinity Rise. So on the resubmission MPS2, I guess what specific question from the FDA is the longer-term follow-up and imaging answering?”

“And then on 5500, just thinking towards the phase three starting next year, I guess, how much will the early line data, including the doxataxel combo, kind of feed into how you designed the path forward for Pivotal?”

“First, on Draxin-Rasib and the metastatic RAS in lung cancer setting, curious which data was shared with the FDA to support breakthrough therapy designation here and if there's any read-through to be made to what we could see from Assolve 301.”

“I guess first, maybe on NK, could you talk a bit about the patient treated with KB801 that had a complete closure? Is this patient still being followed? And I guess how does their disease stage or demographic compare to the population that's being enrolled in EMERALD-1?”